Epidemiological Characterization of Drug Resistance among Mycobacterium tuberculosis Isolated from Patients in Northeast of Iran during 2012-2013. 2015

Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
Department of Infectious Diseases, Mashhad University of Medical Sciences, Mashhad, Iran.

BACKGROUND Tuberculosis is still one of the most important health problems in developing countries and increasing drug resistance is the main concern for its treatment. This study was designed to characterize the drug resistant Mycobacterium tuberculosis isolated from patients suffering from pulmonary tuberculosis in northeast of Iran. METHODS In this cross-sectional study during 2012-2013, drug susceptibility testing was performed on Mycobacterium tuberculosis isolated in northeast of Iran using proportional method. Epidemiological data concerning these strains were also analyzed. RESULTS Among 125 studied isolates, 25 mycobacteria (20%) were diagnosed as nontuberculosis mycobacteria. Among the remaining 100 Mycobacterium tuberculosis isolates, the resistance rates were 7%, 7%, 3%, and 9% against isoniazid, rifampin, ethambutol, and streptomycin, respectively. Four isolates were resistant against both isoniazid and rifampin (MDR tuberculosis). The highest resistance rate was observed among 15-45-year-old patients. The MDR tuberculosis was much more prevalent among those who had previous history of treatment. CONCLUSIONS Considering these findings, DOTS strategy should be emphasized and promptly used in order to prevent further resistance. Regarding the high rate of nontuberculosis mycobacteria, it is recommended that confirmatory tests were performed before any therapeutic decision.

UI MeSH Term Description Entries
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D009170 Nontuberculous Mycobacteria So-called atypical species of the genus MYCOBACTERIUM that do not cause tuberculosis. They are also called tuberculoid bacilli, i.e.: M. abscessus, M. buruli, M. chelonae, M. duvalii, M. flavescens, M. fortuitum, M. gilvum, M. gordonae, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. kansasii, M. marinum, M. obuense, M. scrofulaceum, M. szulgai, M. terrae, M. ulcerans, M. xenopi. Atypical Mycobacteria,Mycobacteria, Atypical,Mycobacterium duvalii,Mycobacterium flavescens,Mycobacterium gilvum,Mycobacterium gordonae,Mycobacterium obuense,Mycobacterium szulgai,Mycobacterium terrae,Mycolicibacter terrae,Mycolicibacterium duvalii,Mycolicibacterium flavescens,Mycolicibacterium gilvum,Mycolicibacterium obuense,Tuberculoid Bacillus,Atypical Mycobacterium,Mycobacterium, Atypical,Non-Tuberculous Mycobacteria,Nontuberculous Mycobacterium
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D005260 Female Females

Related Publications

Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
January 1996, Revista cubana de medicina tropical,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
September 1977, Zhonghua Minguo wei sheng wu xue za zhi = Chinese journal of microbiology,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
January 2014, International journal of molecular and cellular medicine,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
May 2018, Ethiopian journal of health sciences,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
June 2020, BMC infectious diseases,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
July 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
March 1989, Tubercle,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
March 2014, Asian Pacific journal of tropical medicine,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
October 1988, Indian journal of pathology & microbiology,
Ashraf Tavanaee Sani, and Abolfazl Shakiba, and Maryam Salehi, and Hamid Reza Bahrami Taghanaki, and Seiedeh Fatemeh Ayati Fard, and Kiarash Ghazvini
January 2015, Bioinformation,
Copied contents to your clipboard!